Safety and effectiveness of eculizumab in Japanese patients with generalized myasthenia gravis: interim analysis of post-marketing surveillance

BACKGROUND: Eculizumab, a humanized monoclonal antibody targeted to terminal complement protein C5, is approved in Japan for treatment of patients with anti-acetylcholine receptor antibody-positive (AChR+) generalized myasthenia gravis (gMG) whose symptoms are difficult to control with high-dose int...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ther Adv Neurol Disord
Autors principals: Murai, Hiroyuki, Suzuki, Shigeaki, Hasebe, Miki, Fukamizu, Yuji, Rodrigues, Ema, Utsugisawa, Kimiaki
Format: Artigo
Idioma:Inglês
Publicat: SAGE Publications 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7970258/
https://ncbi.nlm.nih.gov/pubmed/33796147
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17562864211001995
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars